Migraine Research in Phoenix: What the PHASES Ubrogepant Study Is Exploring

Migraine is more than a headache. It is a neurologic condition that can involve head pain, nausea, sensitivity to light or sound, visual symptoms, fatigue, and a hard-to-predict interruption of work, family time, and daily plans. Many adults manage attacks with a treatment plan from their own clinician. Others are also interested in whether a research study may be relevant to their experience.

Arizona Neuroscience Research lists the PHASES study (P25-590) among its current migraine research opportunities. The study is described as an observational study of adults with migraine who use ubrogepant for acute treatment. This article explains what an observational migraine study means, why the early “prodrome” phase matters, and how to ask informed questions before considering a Phoenix research screening.

What is the PHASES study?

ANR’s Current Studies page describes PHASES (P25-590) as an observational study assessing changes in migraine-attack severity among adults who use oral ubrogepant. The sponsor’s study page identifies P25-590 as a study of real-world effectiveness when ubrogepant is used during the prodrome phase of migraine attacks. The public study page identifies NCT07310290 as the ClinicalTrials.gov identifier.

Study status, eligibility, locations, visit details, and local enrollment may change. The ANR research team and the current approved study materials are the right sources for individual questions. This post is educational; it does not establish eligibility, recommend a medication, or promise that a person will receive any benefit from research participation.

Observational research is different from a drug trial

In an interventional trial, researchers assign an investigational treatment or study group under a protocol. An observational study generally follows what is happening in routine care without assigning a new experimental intervention. The PHASES study information describes participants receiving ubrogepant as prescribed by their clinician according to routine clinical practice and local labeling.

That distinction matters. Taking part does not mean a research team will prescribe a medicine, change a prescription, or decide what is medically appropriate for you. Medication decisions belong with the qualified clinician managing your care. The research team can explain the protocol, but the study is not a substitute for an individualized migraine evaluation.

What is the prodrome phase of migraine?

For some people, a migraine attack begins before head pain becomes obvious. This earlier period is often called the prodrome phase. It can include yawning, fatigue, mood changes, difficulty concentrating, food cravings, neck discomfort, increased sensitivity to light or sound, or a general sense that an attack is developing. Not everyone has prodrome symptoms, and they can overlap with ordinary stress, sleep changes, or other health concerns.

The PHASES study is interested in real-world treatment during this early phase. That does not mean a person should change when or how they use medication on their own. The study team and the prescribing clinician can explain the protocol and approved use. If you are not sure whether a symptom is part of a migraine attack or whether a medicine is appropriate, ask your clinician rather than relying on a blog post.

Who may be asked to screen?

The sponsor study page lists criteria that include adults with a current clinical diagnosis of migraine or chronic migraine and a history of 4 to 10 migraine days per month with moderate-to-severe headache pain in each of the three months before the first visit. It also describes participants as currently prescribed ubrogepant and having used it for acute migraine treatment for at least three months. These are summaries, not a complete eligibility decision.

Eligibility is determined by the research protocol and screening process. It may depend on health history, medicines, prior research participation, migraine pattern, and other factors. A person can be a good candidate for medical care and still not meet the criteria for one specific study. Screening results are not a judgment about the seriousness of a person’s migraine.

What research screening usually involves

Research screening commonly begins with a phone call or online contact form. A coordinator may ask basic questions about age, diagnosis, current medicines, migraine frequency, and prior care to see whether an in-person conversation may be appropriate. If you move ahead, the team reviews the informed-consent form before conducting protocol-specific procedures.

Consent materials should explain why the study is being done, how long it may last, what information is collected, potential risks and discomforts, confidentiality, compensation or reimbursement if applicable, and whom to contact with questions. Read the form carefully. You can ask for plain-language explanations, take time to decide, and talk it over with a family member or your treating clinician.

Bring useful information

• A current medication and supplement list
• A migraine diary or calendar, if you keep one
• Dates of recent migraine-related urgent-care or emergency visits
• Your prescribing clinician’s information
• Questions about visits, transportation, work schedules, and costs

A brief migraine diary can be especially helpful. It may note the date, symptoms, headache severity, early warning signs, treatment used, and impact on plans. It is not a replacement for professional advice, but it can make the screening conversation more specific.

Questions to ask about PHASES

• Is PHASES currently recruiting at Arizona Neuroscience Research?
• What does the study consider a prodrome symptom or migraine attack?
• How are migraine days and treatment timing recorded?
• How long are participants followed?
• Are visits in person, remote, or both?
• What information will be shared with my regular clinician, if any?
• What happens if my migraine pattern or medication changes during the study?
• Who should I contact if I have an adverse event or need urgent medical care?

It is reasonable to ask whether the study will add burdens such as diaries, electronic surveys, phone calls, or extra clinic visits. The sponsor’s public page says participants are followed for up to 13 weeks and receive ubrogepant as prescribed in routine practice, but the current consent materials should be treated as the authoritative source for your own participation.

Migraine care and research can coexist

Research participation should complement—not replace—ongoing care. Continue working with your usual clinician on diagnosis, medication choices, lifestyle factors, and safety planning. Do not start, stop, or change a prescribed migraine medicine because you are considering a study. Your treating clinician can help you understand what is appropriate for your own health history and other medications.

Some symptoms need immediate attention regardless of whether someone is involved in research. Call 911 for sudden facial droop, one-sided weakness or numbness, trouble speaking, fainting, seizure-like activity, a sudden new severe “worst headache,” sudden vision loss, confusion, chest pain, or another possible emergency. A migraine diagnosis does not make new neurologic symptoms safe to ignore.

Practical planning for Phoenix participants

Before agreeing to a screening appointment, ask about location, parking, accessibility, visit length, remote check-ins, and any required technology. Phoenix heat and traffic can affect travel plans, especially when someone is already dealing with a migraine. If you need an accommodation or language support, ask the coordinator what may be available.

Think about whether a support person should be involved. A family member or friend can help remember questions, track migraine days, or assist with transportation when symptoms are active. They do not need to make the decision for you, but their practical perspective can be useful.

Frequently asked questions

Will joining PHASES give me a new migraine medication?

No. The public study description identifies PHASES as observational and describes ubrogepant being used as prescribed in usual care. The study team does not replace the clinician who manages your medication plan.

Can I join if I have chronic migraine?

Possibly, but only screening can determine eligibility. The sponsor information includes a condition related to migraine days and allows for chronic migraine in certain circumstances. Ask ANR for the current approved criteria instead of assuming you qualify.

Do I have to stay in the study after signing consent?

Participation is voluntary. The informed-consent materials should explain how to withdraw and whether any safety follow-up is recommended. You can ask about this before making a decision.

What if my headache is different from my usual migraine?

New, sudden, severe, or concerning neurologic symptoms should be evaluated promptly. Contact a clinician for advice, and call 911 for possible emergency symptoms. Do not wait for a study visit.

Why a migraine diary can be useful

Research studies often ask participants to record information consistently. For migraine, that may include when an attack started, when a person noticed an early warning sign, which symptoms occurred, whether treatment was used, and how the attack affected ordinary activities. Consistent records are valuable because they help researchers analyze patterns across many participants. They can also help a person and their own clinician notice practical trends.

The goal is accuracy, not perfection. Ask the coordinator which format the protocol uses and what to do if you miss an entry. Do not guess to fill a gap. It is better to tell the team what you remember and ask how the protocol handles missing information.

Considering the time commitment

Even an observational study can involve planning. Before deciding, ask about each expected contact, whether surveys must be completed at certain times, and how the team supports participants who experience a migraine during a scheduled task. Ask whether missed visits can be rescheduled and whether there are limits on other research participation while enrolled.

Consider your current workload, caregiving responsibilities, travel needs, and ability to use a smartphone or electronic diary if required. There is no “right” answer. Research participation should be a feasible choice for the individual, and it is acceptable to decide that the timing is not right.

Participant rights and privacy

Study teams collect health information to answer research questions. The consent form should explain what information is collected, who may see it, how it is protected, and how long it may be kept. Ask what will happen to information already collected if you withdraw. You can also ask how your regular clinician will be informed of anything relevant to care.

Participants may ask questions throughout a study, report concerns, and decide whether continued participation makes sense. If the research team gives you a contact number for study-related questions, keep it with your usual medical contacts. For emergency symptoms, use emergency services instead of waiting for a research response.

Keep your approved materials and write down questions as they arise between visits.

Ask early.

Finding accurate information

For up-to-date local information, visit ANR’s Current Studies page and use Volunteer Today to contact the research team. You can also read the sponsor’s PHASES study page and the linked ClinicalTrials.gov record. Research details change, so confirm every practical detail directly before planning a visit.

This article is educational only. It is not medical advice, does not promise enrollment or individual benefit, and should not be used to choose or change a medication. Talk with your treating clinician and the qualified ANR research team about personal decisions.